The FDA has removed a clinical hold it placed on Gilead Sciences’ experimental HIV-1 drug lenacapavir in December 2021 because of quality concerns about the drug’s borosilicate glass vials.
Source: Drug Industry Daily
The FDA has removed a clinical hold it placed on Gilead Sciences’ experimental HIV-1 drug lenacapavir in December 2021 because of quality concerns about the drug’s borosilicate glass vials.
Source: Drug Industry Daily